Disease Intelligence Boards

—

⬡ Run New Analysis

Unacknowledged Alerts

⚗ Prediction Spotlight — KRAS G12C Subgroup (~1-2% of PDAC)

Adagrasib — KRAS G12C covalent inhibitor

GaiaLab surfaces adagrasib for KRAS-mutant panels. FDA approved December 2022 for KRAS G12C NSCLC. Repurposing signal for the ~1-2% of PDAC patients with G12C.

Key Trial

NCT03785249 — KRYSTAL-1, Phase 1/2 (active, not recruiting)

G12D gap (90% of PDAC)

IMM-1-104 NCT05585320 — Phase 1/2a active; no G12D inhibitor currently FDA approved

Critical caveat: Adagrasib and sotorasib target KRAS G12C — a mutation present in only ~1-2% of PDAC. The dominant mutation is G12D (~90%), which no approved drug directly inhibits.

Full case study: Adagrasib →

⚠ What We Don't Know Yet

KRAS G12D — no approved inhibitor: G12D is present in ~90% of PDAC but lacks a reactive cysteine at position 12, making covalent targeting impossible. Non-covalent and bifunctional degrader strategies are in Phase 1 — the first G12D-specific trial (MRTX1133, NCT05737706) was terminated.
SMAD4 loss — no targeted therapy: SMAD4 loss (~55% of PDAC) predicts resistance to standard chemotherapy and immune checkpoint therapy via stromal activation, but no approved drug exploits or reverses this vulnerability.
BRCA2 + PARP inhibitors in PDAC vs. ovarian: Whether the POLO trial benefit (olaparib maintenance) translates to the same degree as in BRCA2-mutant ovarian cancer is still being established — the desmoplastic PDAC microenvironment creates unique drug delivery and immune barriers not present in ovarian tumors.

📡 LassaAI Outbreak Forecast — Week 22/2026

All 37 Nigerian States: LOW Risk (Wet Season)

Forecast generated by LassaAI outbreak prediction model (XGBoost, AUROC = 0.9994, Recall = 1.000). 0 missed outbreak weeks on 2024–2025 holdout. High-risk season: November through April.

Edo

LOW

Ondo

LOW

Bauchi

LOW

Taraba

LOW

Ebonyi

LOW

Training data

27,861 state-week observations · 37 states · 2011–2026 · 8,138 confirmed cases

Key trials

Ribavirin: NCT02539832 (completed)
Favipiravir: NCT04992026 (recruiting)

Live LassaAI dashboard → 🏥 Clinical decision support → For healthcare workers in Nigeria

⚠ What We Don't Know Yet

Favipiravir vs. ribavirin in humans: Favipiravir shows superior efficacy in NHP models but no completed Phase 2/3 RCT in human Lassa fever has been published as of 2026. Whether NHP advantage translates to human outcomes is the central open question.
Ribavirin resistance: No systematic sequencing of LASV from ribavirin treatment failures has been published. L polymerase resistance variants analogous to those in HCV and influenza have not been characterised in field isolates.
Pregnancy management: CFR in Lassa fever complicating pregnancy exceeds 60%. Favipiravir and molnupiravir carry teratogenicity concerns — no treatment trial has enrolled pregnant patients. Evidence-based guidance for this highest-risk group is absent.

✓ Validated Prediction

Lecanemab (Leqembi) — Anti-amyloid monoclonal antibody

GaiaLab surfaces lecanemab for the APOE / APP / PSEN1 panel. FDA approved January 2023 for early Alzheimer's disease.

Mechanism

Targets amyloid-β protofibrils — the toxic intermediate form before plaque deposition

Key Trial

NCT03887455 — CLARITY AD, Phase 3 (active, not recruiting)

Full case study: Lecanemab →

⚠ What We Don't Know Yet

APOE4/4 subgroup: Whether lecanemab slows cognitive decline in APOE4 homozygotes is under active study — this highest-risk genotype was underrepresented in CLARITY AD and had elevated ARIA risk.
TREM2 causal pathway: The relationship between TREM2 variants and amyloid clearance is associative in population studies — not experimentally confirmed as causal in human models.
PSEN1/2 familial vs. sporadic: Early-onset familial AD driven by PSEN1/PSEN2 mutations may respond differently to anti-amyloid therapies than sporadic late-onset AD — the panel does not distinguish these subtypes.

Top Evidence Items

Loading evidence…